Sophia Genetics launched Sophia DDM Digital Twins, a module within its cloud Sophia DDM environment that creates computational replicas of individual cancer patients using multimodal clinical, genomic and imaging data. CEO Jurgi Camblong said the research‑only tool aims to simulate treatment responses and disease trajectories across longitudinal datasets aggregated from the company’s Unity network. In parallel, UK‑based Genomics Ltd introduced Mystra, an AI‑enabled genomics platform that aggregates GWAS and large‑scale genetic datasets to speed drug target and biomarker discovery. Genomics says Mystra automates evidence synthesis across thousands of studies to help de‑risk early target selection and indication prioritization. Both products reflect industry momentum to deploy machine learning and patient‑level simulation to compress discovery timelines, optimize trial matching and inform translational research — though both companies caution the tools are initially research use only and require clinical validation for diagnostic or therapeutic decision making.